Climb Bio/$CLYM
1D1W1MYTD1Y5YMAX
Capital at risk
About Climb Bio
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
- Ticker
- $CLYM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 29
- Headquarters
- Wellesley Hills, United States
- Website
- climbbio.com
Climb Bio Metrics
BasicAdvanced
$810M
-
-$0.83
0.08
-
Price and volume
Market cap
$810M
Beta
0.08
52-week high
$18.33
52-week low
$1.54
Average daily volume
1.5M
Financial strength
Current ratio
31.452
Quick ratio
30.86
Long term debt to equity
0.003
Total debt to equity
0.005
Profitability
EBITDA (TTM)
-64.628
Management effectiveness
Return on assets (TTM)
-18.45%
Return on equity (TTM)
-27.10%
Valuation
Price to book
3.38
Price to tangible book (TTM)
3.38
Price to free cash flow (TTM)
-18.354
Free cash flow yield (TTM)
-5.45%
Free cash flow per share (TTM)
-0.769
Growth
Earnings per share change (TTM)
20.38%
3-year earnings per share growth (CAGR)
-21.05%
What the Analysts think about Climb Bio
Analyst ratings (Buy, Hold, Sell) for Climb Bio stock.
Analyst projections of the future price of Climb Bio stock.
Climb Bio Financial Performance
Revenues and expenses
Climb Bio Earnings Performance
Company profitability
Upcoming events
No upcoming events
Climb Bio News
AllArticlesVideos
Funds containing Climb Bio
Fund name | Fund size | $CLYM weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.